Advances in urothelial bladder cancer immunotherapy, dawn of a new age of treatment

被引：17

作者：

Aoun, Fouad ^{[1
,2
]}

El Rassy, Elie ^{[3
]}

Assi, Tarek ^{[4
]}

Albisinni, Simone ^{[2
]}

Katan, Joseph ^{[3
]}

机构：

[1] St Joseph Univ, Hotel Dieu France, Dept Urol, Beirut, Lebanon

[2] Inst Jules Bordet, Dept Urol, 1 Rue Heger Bordet, B-1000 Brussels, Belgium

[3] St Joseph Univ, Hotel Dieu France, Dept Oncol, Beirut, Lebanon

[4] Inst Gustave Roussy, Dept Oncol, Paris, France

来源：

IMMUNOTHERAPY | 2017年 / 9卷 / 05期

关键词：

bladder cancer; clinical trials; immunotherapy; PDL-1; inhibitors; PD-1; BACILLUS-CALMETTE-GUERIN; RANDOMIZED-TRIAL; CELL-CARCINOMA; PLUS; CHEMOTHERAPY; CISPLATIN; ATEZOLIZUMAB; MULTICENTER; VINFLUNINE; MECHANISMS;

D O I：

10.2217/imt-2017-0007

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Urothelial bladder cancer displays a high number of somatic mutations that render these tumors more responsive to immunotherapy. Several immunotherapeutic agents were examined in patients with advanced stage urothelial bladder cancer and recently atezolizumab - an (PDL-1) immune checkpoint inhibitor antibody - was approved for the treatment of patients with metastatic disease progressing after platinum combination therapy. Despite the great success, there are still some unanswered questions and ongoing trials that are in progress to define the role of combination therapy and sequencing strategies. The objective of our manuscript is to summarize the most recent data on immunotherapy in advanced urothelial cancer. Current challenges and future perspectives of immunotherapy as a monotherapy or in combination strategies will also be analyzed.

引用

页码：451 / 460

页数：10

共 41 条

[1] Checkpoint inhibitors in bladder and renal cancers: results and perspectives [J].

Aoun, Fouad ;

Kourie, Hampig R. ;

Sideris, Spyridon ;

Roumeguere, Thierry ;

van Velthoven, Roland ;

Gil, Thierry .

IMMUNOTHERAPY, 2015, 7 (12) :1259-1271

[2] EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016 [J].

Babjuk, Marko ;

Boehle, Andreas ;

Burger, Maximilian ;

Capoun, Otakar ;

Cohen, Daniel ;

Comperat, Eva M. ;

Hernandez, Virginia ;

Kaasinen, Eero ;

Palou, Joan ;

Roupret, Morgan ;

van Rhijn, Bas W. G. ;

Shariat, Shahrokh F. ;

Soukup, Viktor ;

Sylvester, Richard J. ;

Zigeuner, Richard .

EUROPEAN UROLOGY, 2017, 71 (03) :447-461

[3]

Balar A, 2016, ANN ONCOL S, V27

[4] Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial [J].

Balar, Arjun V. ;

Galsky, Matthew D. ;

Rosenberg, Jonathan E. ;

Powles, Thomas ;

Petrylak, Daniel P. ;

Bellmunt, Joaquim ;

Loriot, Yohann ;

Necchi, Andrea ;

Hoffman-Censits, Jean ;

Perez-Gracia, Jose Luis ;

Dawson, Nancy A. ;

van der Heijden, Michiel S. ;

Dreicer, Robert ;

Srinivas, Sandy ;

Retz, Margitta M. ;

Joseph, Richard W. ;

Drakaki, Alexandra ;

Vaishampayan, Ulka N. ;

Sridhar, Srikala S. ;

Quinn, David I. ;

Duran, Ignacio ;

Shaffer, David R. ;

Eigl, Bernhard J. ;

Grivas, Petros D. ;

Yu, Evan Y. ;

Li, Shi ;

Kadel, Edward E., III ;

Boyd, Zachary ;

Bourgon, Richard ;

Hegde, Priti S. ;

Mariathasan, Sanjeev ;

Thastrom, AnnChristine ;

Abidoye, Oyewale O. ;

Fine, Gregg D. ;

Bajorin, Dean F. .

LANCET, 2017, 389 (10064) :67-76

[5] Phase III Trial of Vinflunine Plus Best Supportive Care Compared With Best Supportive Care Alone After a Platinum-Containing Regimen in Patients With Advanced Transitional Cell Carcinoma of the Urothelial Tract [J].

Bellmunt, Joaquim ;

Theodore, Christine ;

Demkov, Tomasz ;

Komyakov, Boris ;

Sengelov, Lisa ;

Daugaard, Gedske ;

Caty, Armelle ;

Carles, Joan ;

Jagiello-Gruszfeld, Agnieszka ;

Karyakin, Oleg ;

Delgado, Francois-Michel ;

Hurteloup, Patrick ;

Morsli, Nassim ;

Salhi, Yacine ;

Culine, Stephane ;

von der Maase, Hans .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (27) :4454-4461

[6]

Berghoff AS, 2015, AM SOC CLIN ONCOL ED, V35, pe116

[7] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[8] Immune-based mechanisms of cytotoxic chemotherapy: implications for the design of novel and rationale-based combined treatments against cancer [J].

Bracci, L. ;

Schiavoni, G. ;

Sistigu, A. ;

Belardelli, F. .

CELL DEATH AND DIFFERENTIATION, 2014, 21 (01) :15-25

[9] Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers [J].

Carbognin, Luisa ;

Pilotto, Sara ;

Milella, Michele ;

Vaccaro, Vanja ;

Brunelli, Matteo ;

Calio, Anna ;

Cuppone, Federica ;

Sperduti, Isabella ;

Giannarelli, Diana ;

Chilosi, Marco ;

Bronte, Vincenzo ;

Scarpa, Aldo ;

Bria, Emilio ;

Tortora, Giampaolo .

PLOS ONE, 2015, 10 (06)

[10] Oncology Meets Immunology: The Cancer-Immunity Cycle [J].

Chen, Daniel S. ;

Mellman, Ira .

IMMUNITY, 2013, 39 (01) :1-10

← 1 2 3 4 5 →